RxDoctor Payments DataLook up a doctor →

John Huang, MD

Ophthalmology · Hartford, CTNPI 1801822754

Payments from drug & device makers

$389,578in general payments, 2019–2025

Across 498 payments — averaging $782.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$106K
  • Mallinckrodt Hospital Products Inc.$85K
  • Regeneron Healthcare Solutions, Inc.$53K
  • Astellas Pharma US Inc$41K
  • AbbVie$38K
  • Mallinckrodt Enterprises LLC$18K
  • plus $49K from 22 others

What the payments were for

  • Consulting fees$18,0797%
  • Speaking & faculty fees$233,36087%
  • Travel & lodging$3,6261%
  • Food & beverage$11,5444%
  • Gifts$1800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$389,578 in reported general payments places this provider in the 95th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$3,199,126
Medicare patients
1,021
Services billed
22,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine58$36,834
XiidraLifitegrast30$20,254
Prednisolone Acetate280$18,379
Cyclosporine31$15,156
IlevroNepafenac11$7,971
Ketorolac Tromethamine252$7,333
ProlensaBromfenac Sodium14$5,414
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$4,733
RocklatanNetarsudil Mesylat/Latanoprost11$3,888
CombiganBrimonidine Tartrate/Timolol13$3,762
Tobradex StTobramycin/Dexamethasone16$3,734
Atropine Sulfate100$3,262
Brimonidine Tartrate177$2,845
Bromfenac Sodium18$2,523
MoxifloxacinMoxifloxacin Hcl87$2,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$38,434$40,59771 claims
Bausch & Lomb Americas Inc.Xiidra$81$20,25430 claims
NovartisIlevro$8,051$7,97111 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$103$5,41414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →